tag:blogger.com,1999:blog-36768584.post9213225750383764212..comments2024-03-03T18:49:34.382-05:00Comments on Omics! Omics!: JPM20: Roche Links with Illumina On DiagnosticsKeith Robisonhttp://www.blogger.com/profile/04765318239070312590noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-36768584.post-44732163976344387402020-01-14T13:03:19.911-05:002020-01-14T13:03:19.911-05:00I fully agree with this comment. Even if mid-sized...I fully agree with this comment. Even if mid-sized company, it is very difficult to work on cutting edge innovation unless the very top management understand the technologies pros and cons thoroughly. Fingered crossed with Roche, but let's see. They already kicked out two companies from their portfolio.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-36768584.post-42565441219835682952020-01-14T06:23:08.073-05:002020-01-14T06:23:08.073-05:00"ONT made noises they had solid with great bl..."ONT made noises they had solid with great blocking potential across the nanopore space, but surely Roche bought Genia thinking that wouldn't be an insurmountable problem. Did they change their mind? Or was the technology only seemingly close to launch but in reality there was a great chasm that could not be bridged? "<br /><br />The due diligence here possibly wasn't up to scratch. <br /><br />Also making sequencers from scratch, especially single molecule ones, just isn't as easy as many people think. <br /><br />Institutionalised large company culture doesn't really fit with cutting edge innovation.Anonymousnoreply@blogger.com